The group is recognized for developing a revolutionary nuclear magnetic resonance (NMR) method for ‘fingerprinting’ the structure of biopharmaceuticals. Using a new form of NMR data collection and processing, they were able to determine, with atomic resolution, the structure of a monoclonal antibody protein, a feat previously thought to be impossible. Their work provides a new fundamental measurement tool to protein drug manufacturers and regulators, supporting the development of lower-cost generic drugs that promise to greatly increase patient access to these innovative life-saving medications.